Updated Jul 16, 2026 · Last SEC filing 2026-07-13
Dianthus Therapeutics, Inc. /DE/ (DNTH) has filed 11 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-13. 3 Form 8-K material event filings were reported by DNTH in the last 90 days. 3 Form 144 notices of proposed sale were filed for DNTH stock. InsiderAlpha tracks every DNTH SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SIC classification | Pharmaceutical Preparations (SIC 2834) |
|---|---|
| SEC CIK | 0001690585 |
| Form 4 filings (90d) | 11 |
|---|---|
| Form 8-K filings (90d) | 3 |
| Form 144 notices (90d) | 3 |
| Latest Form 4 filing | 2026-07-13 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Savitz Ryan | EVP, CFO & CBO | M — Option exercise [10b5-1] | 31.2K | $21.77 | $680K | SEC | |
| Savitz Ryan | EVP, CFO & CBO | S — Open-market sale [10b5-1] | 10.4K | $100.22 | $1.04M | SEC | |
| Savitz Ryan | EVP, CFO & CBO | S — Open-market sale [10b5-1] | 5.6K | $101.97 | $568K | SEC | |
| Savitz Ryan | EVP, CFO & CBO | S — Open-market sale [10b5-1] | 15.3K | $101.24 | $1.55M | SEC | |
| Veness Adam M | SVP, General Counsel and Sec. | M — Option exercise | 30.0K | $17.88 | $536K | SEC | |
| Veness Adam M | SVP, General Counsel and Sec. | S — Open-market sale | 16.8K | $80.34 | $1.35M | SEC | |
| Veness Adam M | SVP, General Counsel and Sec. | S — Open-market sale | 13.2K | $81.38 | $1.08M | SEC | |
| Randhawa Simrat | EVP, Head of R&D | S — Open-market sale | 4.2K | $91.37 | $380K | SEC | |
| Randhawa Simrat | EVP, Head of R&D | M — Option exercise | 9.4K | $22.07 | $207K | SEC | |
| Randhawa Simrat | EVP, Head of R&D | S — Open-market sale | 16.9K | $90.72 | $1.54M | SEC | |
| Randhawa Simrat | EVP, Head of R&D | M — Option exercise | 4.0K | $8.44 | $34K | SEC | |
| Randhawa Simrat | EVP, Head of R&D | S — Open-market sale | 5.4K | $89.72 | $487K | SEC | |
| Randhawa Simrat | EVP, Head of R&D | M — Option exercise | 6.9K | $17.88 | $124K | SEC | |
| Randhawa Simrat | EVP, Head of R&D | M — Option exercise | 6.2K | $21.77 | $136K | SEC | |
| Soteropoulos Paula | Insider | M — Option exercise | 599 | $8.44 | $5K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Dianthus Therapeutics, Inc. /DE/ (DNTH). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Randhawa Simrat | 11 | $2.90M |
| Savitz Ryan | 5 | $3.84M |
| Soteropoulos Paula | 4 | $56K |
| Veness Adam M | 4 | $2.96M |
| KANGO SUJAY | 1 | — |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in DNTH insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live DNTH dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.